The Liver Meeting 2022-Alcohol-associated Liver Disease SIG and Nonalcoholic Fatty Liver Disease SIG Program: NAFLD and ALD: Similarities, Differences, and Learning Objectives: Targets, Treatments and Outcomes. PART 2

Alcohol-associated Liver Disease SIG and Nonalcoholic Fatty Liver Disease SIG Program: NAFLD and ALD: Similarities, Differences, and Learning Objectives: Targets, Treatments and Outcomes. PART 2

Back to course

Video Transcription

Video Summary

This video addresses the topic of obesity and metabolic syndrome in the context of liver transplantation. The presenters discuss the epidemiology of these conditions and their impact on selection and outcomes for liver transplant recipients. They note that the prevalence of metabolic syndrome has increased over time in the general population, with higher rates seen in certain demographics. In liver transplant recipients, the prevalence of metabolic syndrome doubles within one year of transplant, particularly in patients with end-stage liver disease. Factors driving this association include immunosuppression, surgical factors, and systemic effects of cirrhotic physiology. The presenters emphasize the need for accurate measurement of obesity in this population, noting that BMI alone is a poor indicator. They discuss the importance of assessing for fluid retention and the risk of malnutrition in obese patients. The prevalence of obesity among liver transplant recipients in the US has decreased since 2010, but still remains significant. The presenters conclude by highlighting the importance of addressing obesity and metabolic syndrome in the evaluation and management of liver transplant candidates.

Keywords

obesity

metabolic syndrome

liver transplantation

epidemiology

selection

outcomes

prevalence

end-stage liver disease

immunosuppression

surgical factors

cirrhotic physiology

BMI

evaluation